Granahan Investment Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Granahan Investment Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-4,472	Closed	-$1.34M	–	191
2019 Q2	$1.34M	Sell	4,472 -90	-2%	-$37.5K	0.07%	160
2019 Q1	$2.05M	Sell	4,562 -573	-11%	-$251K	0.11%	149
2018 Q4	$2.35M	Sell	5,135 -94	-2%	-$58.3K	0.17%	122
2018 Q3	$4.75M	Buy	5,229 +143	+3%	+$94.4K	0.26%	104
2018 Q2	$2.98M	Buy	5,086 +628	+14%	+$410K	0.18%	135
2018 Q1	$2.9M	Buy	4,458 +1,806	+68%	+$1.36M	0.21%	129
2017 Q4	$969K	Buy	2,652 +338	+15%	+$129K	0.08%	167
2017 Q3	$708K	Buy	2,314 +1,921	+489%	+$729K	0.06%	162
2017 Q2	$188K	Buy	393 +210	+115%	+$159K	0.02%	223
2017 Q1	$228K	Buy	+183	New	+$88.1K	0.02%	207

Other funds holding HTGM

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Granahan Investment Management's HTGM Position: Q3 2019 in Review

Granahan Investment Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2019, closing a stake of 4,472 shares — an estimated $1.34M sold.

Granahan Investment Management first reported a position in HTGM in Q1 2017 and held it in 10 quarters. The position peaked at $4.75M in Q3 2018. 44 funds tracked by Wall St. Rank hold HTGM as of Q3 2019.

Granahan Investment Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Granahan Investment Management sold 4,472 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2019, an estimated $1.34M.
Granahan Investment Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2017 and held it in 10 quarters.
Granahan Investment Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $4.75M in Q3 2018.
44 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2019.

Based on Granahan Investment Management's 13F filing for Q3 2019, filed 15 Nov 2019.